Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Usher syndrome in which the cause of the disease is a mutation in the WHRN gene.
Features include always present findings: Hearing loss (hearing impairment), Nyctalopia, and Rod-cone dystrophy. 4 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Ears | 2 | Hearing loss (hearing impairment), Abnormal vestibular function |
Age of onset: at birth, adulthood.
WHRN function has not been fully characterized.
Usher syndrome type 2D is caused by mutations in the WHRN gene on chromosome 9.
USH2A. Deleterious null (e.g., nonsense, frameshift, splicing) variants are associated with USH2, whereas homozygous missense variants that generate partially functional proteins typically cause nonsyndromic RP . The visual phenotype in individuals with USH2A-USH2 pathogenic variants is associated with more severe RP compared with nonsyndromic USH2A-RP . The hearing phenotype in individuals with USH2A-USH2 is more severe and progressive in individuals with one or more deleterious USH2A variants . designated retinal disease-specific pathogenic variants in USH2A that cause RP with preservation of normal hearing. While these individuals did not report hearing loss, audiometric testing found variable hearing loss in a substantial number.
Usher syndrome type II (USH2) should be suspected in individuals with:
Congenital (i.e., prelingual) sensorineural hearing loss that is mild to moderate in the low frequencies and severe to profound in the higher frequencies (see Hereditary Hearing Loss and Deafness Overview);
Intact or variable vestibular responses;
No approved treatments are currently available for Usher syndrome type 2D. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with Usher syndrome type II (USH2), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 5. Recommended Evaluations Following Initial Diagnosis in Individuals with Usher Syndrome Type II
Table 7. Recommended Surveillance for Individuals with Usher Syndrome Type II
System/Concern |
|---|
No clinical trials have been registered for Usher syndrome type 2D.
8 publications have been identified in PubMed for Usher syndrome type 2D. Research spans Basic Science / Preclinical (75%), Case Report / Case Series (13%), and Gene Therapy / Novel Therapeutics (13%).
Zou J (2026). [PMID: 41654259](https://pubmed.ncbi.nlm.nih.gov/41654259/). *Molecular & cellular proteomics : MCP*. [Basic Science / Preclinical]
Bae HG (2025). [PMID: 40360853](https://pubmed.ncbi.nlm.nih.gov/40360853/). *Journal of the Association for Research in Otolaryngology : JARO*. [Basic Science / Preclinical]
Stemerdink M (2025). [PMID: 40037841](https://pubmed.ncbi.nlm.nih.gov/40037841/). *Genome research*. [Basic Science / Preclinical]
Lewis TR (2025). [PMID: 39930192](https://pubmed.ncbi.nlm.nih.gov/39930192/). *Advances in experimental medicine and biology*. [Basic Science / Preclinical]
Stemerdink M (2025). [PMID: 41036464](https://pubmed.ncbi.nlm.nih.gov/41036464/). *Molecular therapy. Nucleic acids*. [Gene Therapy / Novel Therapeutics]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 1:59 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Usher syndrome type 2D
Usher syndrome type II (USH2) is characterized by moderate-to-severe sensorineural hearing loss at birth and retinitis pigmentosa (RP) that begins in late adolescence or early adulthood. Some individuals also have vestibular loss . Table 2. Select Features of Usher Syndrome Type II
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Hearing loss | 100% | High-frequency loss which is usually stable |
RP | 100% | Variable age of onset rate of progression |
Vestibular loss | 40%-80% | Usually asymptomatic but identifiable on specialized testing1 RP = retinitis pigmentosa 1. The hearing loss in USH2 is typically congenital and bilateral, occurring predominantly in the higher frequencies and ranging from moderate to severe. |
Source: GeneReviews — "Usher Syndrome Type II"
Source: GeneReviews — "Usher Syndrome Type II"
Normal general health and intellect; otherwise normal physical examination;
A family history consistent with autosomal recessive inheritance.
The diagnosis of USH2 is established in a proband with the clinical features and family history. Identification of biallelic pathogenic (or likely pathogenic) variants in one of the genes listed in establishes the diagnosis if clinical features are inconclusive.
Source: GeneReviews — "Usher Syndrome Type II"
Often, a family with more than one affected sib is thought to have nonsyndromic hearing loss (NSHL) (see Hereditary Hearing Loss and Deafness Overview) until the oldest is diagnosed with retinitis pigmentosa (RP). Subsequent visual evaluation often reveals the presymptomatic early stages of RP in younger affected sibs. Pathogenic variants associated with NSHL and RP can be inherited independently by a single individual whose symptoms mimic those of Usher syndrome . Larger families lessen the statistical probability of this occurrence because at least one sib is likely to inherit one pathogenic variant without the other. NSHL and RP are both relatively common, with frequencies of 1:1,000 and 1:4,000, respectively, and are characterized by extreme genetic heterogeneity (to date, 110 genes have been associated with NSHL and 80 genes have been associated with RP). Hereditary disorders characterized by both sensorineural hearing impairment and decreased visual acuity to consider in the differential diagnosis of Usher syndrome type II (USH2) are summarized in . Table 4. Genes of Interest in the Differential Diagnosis of Usher Syndrome Type II
Gene(s) | Disorder | MOI | Clinical Characteristics | Comment |
|---|---|---|---|---|
USH1 | AR | Congenital bilateral profound SNHL, vestibular areflexia, adolescent-onset RP | Children w/USH1 are usually do not walk until age 18 mos to 2 yrs due to vestibular involvement (those w/USH2 usually walk at age ~1 yr). CLRN1 | — |
HARS1 | USH3 (OMIM 276902, 614504) | AR | Postlingual progressive SNHL, late-onset RP, variable impairment of vestibular function | Some persons w/USH3 may have profound HL vestibular disturbance thus be clinically misdiagnosed w/USH1 or USH2.1 |
PEX1PEX6PEX12(13 genes)2 | Zellweger spectrum disorder (ZSD)3 | Intermediate/milder ZSD | AR(AD)4 | Mainly sensory deficits /or mild developmental delay; intellect may be normal. |
Source: GeneReviews — "Usher Syndrome Type II"
Genetic testing for WHRN is available. Testing is considered confirmatory for diagnosis.
System/Concern | Evaluation | Comment |
|---|
Audiology | Otoscopy, puretone audiometry, assessment of speech perception | Consider auditory brain stem response (ABR), electrocochleography (ECOG), and distortion product otoacoustic emission (DPOAE). Speech and sentence tests with hearing aids will determine if cochlear implantation offers better rehabilitation than hearing aids. Vestibular |
function | Rotary chair, calorics, electronystagmography, ocular cervical myogenic evoked potentials, video head impulse testing, computerized posturography | Persons describing imbalance or dizziness should undergo comprehensive vestibular testing to guide rehabilitation. |
Ophthalmology | Fundus photography, VA, VF (Goldmann perimetry, Humphrey perimetry, Dark adapted rod perimetry), ERG, OCT, FAF | Fundus photography documents extent of pigmentation RPE atrophy; VA is often maintained until late in disease; VF maps extent of functional peripheral vision, retinal sensitivities, functional rod cone responses. |
counseling | By genetics professionals1 | To inform affected individuals families re nature, MOI, implications of USH2 in order to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Usher Syndrome Type II Manifestation/Concern | Treatment | Considerations/Other |
Hearing loss | Hearing aids | Young children benefit from early fitting of hearing aids speech training. Cochlear implantation |
Imbalance | Vestibular rehab | Neurologically active medications or sedatives can aggravate mild vestibular dysfunction. describe the visual outcomes and rehabilitation of a one individual with USH2 that underwent Argus II prosthesis surgery. Surveillance Table 7. |
Recommended Surveillance for Individuals with Usher Syndrome Type II System/Concern | Evaluation | Frequency |
Hearing loss | Audiometry tympanometry w/hearing aids or cochlear implant to assure adequate auditory stimulation | Annually, incl testing w/hearing aids in place |
Cataracts | Ophthalmologic eval | Annually from age 20 yrs or age of diagnosis Cystoid macular edema |
pigmentosa | Fundus photography, VA, VF (Goldmann perimetry, Humphrey perimetry, dark adapted rod perimetry), ERG, OCT, FAF | Annually from age 10 yrs or age of diagnosis ERG = electroretinography; FAF = fundus autofluorescence; OCT = optical coherence tomography; VA = visual acuity; VF = visual field Agents/Circumstances to Avoid Progressive loss of peripheral vision impairs the ability to safely drive a car. |
Source: GeneReviews — "Usher Syndrome Type II"
Competition in various sports requiring a full range of vision may be difficult and possibly dangerous. Progressive loss of peripheral vision impairs the ability to safely drive a car. An Esterman visual field test (automated Humphrey, static visual field analyzer) with both eyes open during testing is a helpful measure to assess degrees of peripheral vision along the midline. Night driving is impaired very early.
Source: GeneReviews — "Usher Syndrome Type II"
QR-421 antisense treatment. Study to Evaluate Safety and Tolerability of QR-421a in Subjects with RP Due to Mutations in Exon 13 of the USH2A Gene (Stellar). This is an interventional, Phase I/II clinical trial to evaluate the safety of an antisense oligonucleotide (ASO) therapy to treat RP in individuals with USH2 due to specific USH2A pathogenic variants. This study is active and recruiting (see ClinicalTrials.gov). C-18-04 antioxidant treatment. Safety and Efficacy of NPI-001 Tablets for Retinitis Pigmentosa Associated with Usher Syndrome (SLO RP). This is an interventional, two-year, Phase I/II clinical trial to evaluate the safety and efficacy of NPI-001 tablets in individuals with RP associated with Usher syndrome. This trial is active and recruiting (see ClinicalTrials.gov).
Source: GeneReviews — "Usher Syndrome Type II"
View trials for Usher syndrome type 2D
Evaluation
Frequency |
|---|
Hearing loss | Audiometry tympanometry w/hearing aids or cochlear implant to assure adequate auditory stimulation | Annually, incl testing w/hearing aids in place |
Cataracts | Ophthalmologic eval | Annually from age 20 yrs or age of diagnosis Cystoid macular edema |
pigmentosa | Fundus photography, VA, VF (Goldmann perimetry, Humphrey perimetry, dark adapted rod perimetry), ERG, OCT, FAF | Annually from age 10 yrs or age of diagnosis ERG = electroretinography; FAF = fundus autofluorescence; OCT = optical coherence tomography; VA = visual acuity; VF = visual field |
Source: GeneReviews — "Usher Syndrome Type II"
Phenotype severity distribution: 3 always present features.
Chentoufi FE (2025). [PMID: 40389825](https://pubmed.ncbi.nlm.nih.gov/40389825/). *Journal of biomolecular structure & dynamics*. [Basic Science / Preclinical]
Gélvez N (2025). [PMID: 41060164](https://pubmed.ncbi.nlm.nih.gov/41060164/). *Biomedica : revista del Instituto Nacional de Salud*. [Case Report / Case Series]
Aguilar C (2024). [PMID: 38974964](https://pubmed.ncbi.nlm.nih.gov/38974964/). *iScience*. [Basic Science / Preclinical]